Background: Blood oxidant profile affects tumor cell eradication in cancer patients undergoing thermotherapy. 
Objective: The study objectives were the determination of the blood oxidant/antioxidant balance in colorectal cancer (CRC) before and after the XELOX regimen combined with Bevacizumab, and also the effect of treatment on the oxidative stress markers during the first cycle of chemotherapy.
Methods: In this case-control study, 50 healthy controls and 41 colorectal patients were recruited at Popular Hospital Establishment and Avicène Medical Clinic (Maghnia city, Algeria) during 2019. Blood samples were collected from participants before and after treatment. To determine the fluctuations of redox status vis-à-vis of treatment, levels of oxidant and antioxidant parameters were measured using spectrophotometry. Data were analyzed using independent samples t-test and Pearson’s correlation coefficients.
Results: The obtained results highlighted the presence of oxidative stress in CRC cases compared to controls. In CRC, high levels in malondialdehyde (3.06±0.65 µmol/L, p=0.090), superoxide anion (8.38±0.21 µmol /L, p=0.478), carbonyl proteins (0.453±0.11 nmol/mg protein; p=0.292), and peroxynitrite (12.8±4.27 µmol/mL, p=0.093) with significant difference in nitric oxide value (26.07±5.50µmol /L; p=0.0001) were depicted before treatment and, and low total activities of superoxide dismutase (37.81±0.07 U/gHb; p=0.0001) and catalase (29.33±4.99 U/gHb; p=0.0001) with a decrease of glutathione (2.92±0.9 mmol/ L; p=0.0001) concentration were recorded. After treatment, malondialdehyde (1.59±0.11 µmol/L; p=0.003), superoxide anion (7.68±0.17 µmol/L; p=0.003), and carbonyl proteins (0.311±0.02 nmol/mg protein; p=0.024) rates decreased at the opposite of nitric oxide (57.46±9.69 µmol/L; p=0.001) and peroxynitrite (20±3.82 µmol/mL; p=0.002) levels, which increased markedly alike the activities of superoxide dismutase (379.54±0.66 U/gHb; p=0.05) and catalase (131.92±5.83 U/gHb; p=0.0001), and reduced glutathione level (16.11±0.57 mmol/L; p=0.0001) raised significantly. 
Conclusion: Limiting the efficiency of drug treatment inhibits the eradicating effect of high blood levels of nitric oxide and peroxynitrite for tumor cells, where cancer patients are nonresponsive to chemotherapeutic treatment. Blood oxidant/antioxidant levels should be an effective guideline for directing the response to cancer treatments, especially the risk of resistance to anti-tumor drugs. Redox homeostasis, which is linked to nutritional profile and lifestyle, should be included in medical check-ups to achieve a better prediction of treatment response.
Keywords: Antioxidants; Oxidative stress; Colorectal cancer; Chemotherapy


» HTML Fulltext    » PDF Fulltext    » doi: 10.19082/7822

The  most recent editorial (June 2021)

Ethics of Publishing Case Reports: Do We Need Ethics Approval and Patient Consent?

An editorial by Dr. Mehrdad Jalalian

Read more.

The worldwide spread of COVID-19 as an emerging, rapidly evolving situation, and the dramatic need of urgent medicine or vaccine, has rapidly brought new hypotheses for pathophysiology and potential medicinal agents to the fore. It is crucial that the research community provide a way to publish this research in a timely manner.


To contribute to this important public health discussion, the Electronic Physician Journal is excited to announce a fast-track procedure to help researchers publish their articles on COVID-19 related subjects that fall under the broad definition of public health, internal medicine, and pharmacology. We are especially welcome to all hypotheses about the pathological basis of the COVID-19 infection and the possible characteristics of potential medicine and vaccine. Submit your manuscript here


Our previous editorial (June 2020)

Lessons from COVID-19 pandemic and the Morocco’s success story.

An editorial by Dr. Benksim Abdelhafid (Morocco)

Read more.


The 6th World Conference on Research Integrity (WCRI) is to be held on June 2-5, 2019 in Hong Kong.

The WCRI is the largest and most significant international conference on research integrity. Since the first conference in Lisbon in 2007, it has given researchers, teachers, funding agencies, government officials, journal editors, senior administrators, and research students opportunities to share experiences and to discuss and promote integrity in research. Read more:


TDR Clinical Research and Development Fellowships

Call for applications

Deadline for submission: 7 March 2019, 16:00 (GMT)

TDR provides fellowships for early- to mid-career researchers and clinical trial staff (e.g. clinicians, pharmacists, medical statisticians, data managers, other health researchers) in low- and middle-income countries (LMICs) to learn how to conduct clinical trials. Read more:

Meta-Analysis Workshops in New York, USA, and London, UK, in April and May 2019

Don't miss this exceptional opportunity to learn how to perform and report a Meta-analysis correctly. Two Meta-analysis workshops are organized in April and May 2019 by Dr. Michael Borenstein in New York, USA (April 08-10, 2019) and London, UK (May 27-29).

About the Instructor

Dr. Michael Borenstein, one of the authors of Introduction to Meta-Analysis, is widely recognized for his ability to make statistical concepts accessible to researchers as well as to statisticians. He has lectured widely on meta-analysis, including at the NIH, CDC, and FDA. Read more: